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Background: Neuroborreliosis is a tick-borne infectious disease of the nervous system caused by Borrelia burgdorferi.
Common clinical manifestations of neuroborreliosis are cranial nerve dysfunctions, polyradiculoneuritis, and
meningitis. Diagnosis is usually based on clinical presentation, serologic testing, and analysis of cerebrospinal fluid.
Many aspects of pharmacological treatment, such as choice of drug, dosage, and duration are subject of intense
debate, leading to uncertainties in patients and healthcare providers alike. To approach the questions regarding
pharmacological treatment of neuroborreliosis, we will perform a systematic review.
Methods: We will perform a comprehensive systematic literature search for potentially eligible studies that report
outcomes after pharmacological interventions. To adequately consider the wealth of research that has been
conducted so far, this review will evaluate randomized controlled trials (RCTs) and non-randomized studies on
treatment of neuroborreliosis. We will assess potential risk of bias for each RCT meeting our selection criteria using
the Cochrane risk of bias tool for RCTs. For non-randomized studies, we will use the Newcastle-Ottawa Scale and
the recently piloted Cochrane risk of bias tool for non-randomized studies. Our primary outcome of interest will be
neurological symptoms and the secondary outcomes will be disability, patient-reported outcomes (quality of life,
and, if reported separately from other neurological symptoms, pain, fatigue, depression, cognition, and sleep),
adverse events, and cerebrospinal fluid pleocytosis. Pooling of data and meta-analysis will only be deemed justified
between studies with similar design (e.g., RCTs are only combined with other RCTs), characteristics (e.g., similar
populations), and of acceptable heterogeneity (I2 < 80%). Pooled estimates will be calculated using RevMan
software. Prespecified subgroup analyses will evaluate groups of antibiotics, length of antibiotic treatment, and
different doses of doxycycline. We will assess the quality of evidence using the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach.
Discussion: This systematic review will summarize the available evidence from RCTs and non-randomized studies
regarding pharmacological treatment of neuroborreliosis. The available evidence will be summarized and discussed
to provide a basis for decision-making for patients and healthcare professionals.
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Lyme neuroborreliosis is a tick-borne infectious disease
caused by the gram-negative spirochete bacterium Borre-
lia burgdorferi sensu lato. Transmission of B. burgdorferi
occurs via bites by the tick species Ixodes ricinus in
Europe and Ixodes scapularis and Ixodes pacificus in the
United States. Different species of B. burgdorferi show
distinct patterns of distribution, whereas Borrelia garinii,
B. afzelii, and B. burgdorferi sensu stricto are common in
Europe; in the USA, B. burgdorferi sensu stricto predom-
inates [1]. The different genospecies seem to be associ-
ated with distinct clinical manifestations, i.e., B. garinii
being more closely associated with neurological manifes-
tations of borreliosis than other species [1]. Affection of
the nervous system occurs in approximately 15% of all
patients with lyme borreliosis [2]. Common clinical ma-
nifestations of neuroborreliosis are polyradiculoneuritis
(Bannwarth’s syndrome, 63.75% of all cases), in 60%
accompanied by cranial nerve dysfunctions (most fre-
quently facial palsy), and meningitis (23.75%) [3,4]. To a
lesser extent, affections of the central nervous system
like encephalitis and myelitis occur (12.5%) [4]. Other,
rarer manifestations are borrelia-induced vasculitis (0.3%)
and myositis (case reports) [5-8]. Beside nervous system
affections, B. burgdorferi sensu lato can affect multiple
other organ systems. In Europe, manifestations include
the early developing erythema migrans (89%), acroderma-
titis atrophicans (1%), lyme arthritis (5%), or lyme carditis
(<1%) [1,9]. Diagnosis of neuroborreliosis is usually based
on clinical presentation, serologic testing, and analysis of
cerebrospinal fluid (CSF) [10]. Tiered case definitions exist
regarding likelihood of diagnosis depending on diagnostic
results [3,11]. Different authors report variable sensitivities
of this approach, and other diagnostic strategies of unclear
accuracy have been suggested [12-14]. Controversy exists
also on the field of therapy, where choice, route of admin-
istration, and length of treatment are subject of intense
debate. The guidelines of the Infectious Diseases Society
of America (IDSA), the European Federation of Neuro-
logical Societies (EFNS), and the evidence-based prac-
tice parameters of the American Academy of Neurology
(AAN) recommend antibiotic treatment with a duration
of up to 21–28 days [10,15,16], whereas guidelines of
the International Lyme and Associated Diseases Society
(ILADS) states that several months of antibiotic therapy
are often required [17]. Furthermore, the ILADS guideline
states that short-course antibiotic treatment shows high
failure rates for treatment of neuroborreliosis. Choice of
antibiotic agent for treatment of neuroborreliosis is also a
matter of ongoing controversy. IDSA, EFNS, and AAN
guidelines usually recommend cephalosporin antibiotics,
doxycycline, or penicillin antibiotics, whereas some au-
thors recommend treatment with other substances, like
carbapenem antibiotics, metronidazole, or antimalarialdrugs such as hydroxychloroquine for certain subgroups
of patients [17]. The use of combination therapy (use of
multiple antibiotics concurrently) for the treatment of
neuroborreliosis is advocated by the ILADS, whereas the
IDSA, EFNS, and AAN discourage the use of antibiotic
combination regimes. The optimal dosage of the orally ad-
ministered antibiotic doxycycline remains unclear. Studies
investigating the effects of doxycycline on people with
neuroborreliosis examined daily doses ranging from 200–
400 mg [18-20]. Accordingly, the IDSA and EFNS guide-
lines recommend doxycycline doses of 200 mg, whereas
the guidelines of the Deutsche Gesellschaft für Neurologie
(DGN) and AAN guidelines suggest applying higher doses
of up to 400 mg [10,15,16,21]. These various, partly con-
tradicting recommendations lead to a considerable am-
biguity and doubt in patients and healthcare providers
alike when facing treatment decisions for neuroborre-
liosis. Therefore, it seems necessary to review, evaluate,
and summarize the available evidence for drug treatment
of neuroborreliosis for making evidence-based clinical re-
commendations. To adequately consider the wealth of
research that has been conducted and to overcome limita-
tions of availability of only few RCTs for a limited number
of important questions with regard to optimal treatment,
this review will evaluate randomized controlled trials and
non-randomized studies for treatment of neuroborreliosis.
Adding non-randomized studies to systematic reviews can
have certain advantages. Non-randomized studies seem to
be more suitable for the detection of adverse events than
RCTs and may have longer follow-up periods [22].Method/design
Objectives
To assess the efficacy and safety of pharmacological inter-
ventions in the treatment of adults with neuroborreliosis.Types of studies
This review will evaluate randomized controlled trials
and non-randomized studies for treatment of neurobor-
reliosis. By assessing randomized and non-randomized
studies, we will consider the wealth of research that has
been conducted and overcome scarcity and limitation
in scope of available RCTs. All studies comparing any
pharmacological treatment to any other treatment,
placebo, or no treatment will be screened for eligibil-
ity. If studies report no comparison group for an in-
tervention, their results will only be reported narratively
in an appendix to capture the available literature. Stu-
dies without control group will not be used to calcu-
late pooled estimates and will not be subject to a
separate risk of bias assessment. Single case reports
will not be reviewed, but case series greater than five
patients will be considered.
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Studies which evaluate adults with clinically diagnosed
neuroborreliosis will be included. Diagnosis of neuro-
borreliosis is based upon the clinical case definition by
Halperin and Kaiser [3,11]. This case definition dis-
tinguishes between ‘possible’, ‘probable’, and ‘definite’
neuroborreliosis describing an increased likelihood of
neuroborreliosis based on clinical and laboratory param-
eters. For the diagnosis of ‘possible’ neuroborreliosis, the
presence of neurological symptoms suggestive of lyme
neuroborreliosis without other obvious reasons are re-
quired, additionally to one of the following criteria: bor-
relia antibodies in serum, CSF pleocytosis, intrathecal
synthesis of borrelia-specific antibodies, or a verified
erythema migrans during the past 4 months. Serology
should be performed in a two-staged approach, the first
step being a sensitive ELISA and the second a more spe-
cific immunoblot [3,11,23]. For ‘probable’ neuroborre-
liosis, a CSF analysis with pleocytosis and intrathecal
production of IgG is mandatory. For the diagnosis of
‘definite’ neuroborreliosis, additional positive intrathecal
synthesis of borrelia-specific antibodies is mandatory.
Positive findings for PCR or culture of B. burgdorferi in
CSF are supportive of the diagnosis but have a high false
negative rate. Studies regarding patients with ‘post-lyme
disease’, defined as people with persistent symptoms in
the absence of evidence for ongoing infection, will be
excluded.
Types of interventions
We will consider any pharmacological treatment, includ-
ing combinations of treatments. Main interventions
which we are expecting are the following: antibiotics,
steroids, analgesic agents, and phytotherapeutics. We
plan to compare any of these interventions with pla-
cebo/no intervention or any other of these types of in-
terventions separately. Both for antibiotics and steroids,




1. Neurological symptoms after treatment.
Neurological symptoms should be measured by a
validated method (either assessed by a patient or
clinical staff, e.g., via the Neurological Impairment
Scale (NIS) or in analogy to the Expanded Disability
Status Scale (EDSS) [24,25]). When information is
lacking or no valid method was used, which is
assumed to be the case in the majority of studies,
neurological symptoms will be considered as defined
by the original authors of the study. If several time
points are reported in a primary study, data fromthe last reported time point will be considered. If
data permits, results will be presented for short term
follow-up (1 to 3 months following the start of
treatment) and for long term follow-up (4 or more
months following the start of treatment). If multiple
time points are reported for short- or long-term
outcome, we will consider the latest time point
reported. If data permits, we will interpret
neurological symptoms as a continuous outcome
using post-intervention scores. Lack of validated
measurement of outcomes will be considered in the
risk of bias assessment and robustness of data
evaluated in a sensitivity analysis.
Secondary outcomes
1. Adverse events. We will consider any adverse event
as defined and reported by the original authors.
Adverse events will be reported as serious adverse
events when they require hospitalization, are
life-threatening or fatal.
2. Overall disability after treatment at short term
follow-up (1 to 3 months following the start of
treatment) and at long term follow-up (4 or more
months following the start of treatment). Disability
should be measured with a validated scale, e.g., the
modified Rankin scale [26]. If several time points are
reported, data from the last time point will be
considered. If data permits, results will be presented
for short term follow-up (1 to 3 months following
start of treatment) and for long term follow-up (4 or
more months following start of treatment). Disability
will be treated as a continuous outcome. If other
validated scales were used by the original authors,
measurements of disability will be considered as
stated by the authors.
3. Measures of patient reported outcomes, as long as
they are measured by a validated scale, at 1 to
3 months and at 4 or more months following the
start of treatment. This will be regarded as a
continuous outcome. The main patient reported
outcome of interest is health-related quality of life.
Other relevant patient reported outcomes that will
be reported, if assessed separately from other
neurological symptoms and quality of life, will be
pain, fatigue, depression, cognition, and sleep.
Improvement will be considered according to the
minimum important difference (MID), if available, of
each used validated scale. When no validated scale
was used to provide outcome data, improvement will
be considered as stated by the original authors.
4. Cerebrospinal fluid pleocytosis after treatment. If
several time points are reported in a primary study,
data from the last reported time point will be
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outcome.
Search methods for identification of studies
Electronic searches
We will search the databases MEDLINE (via Ovid, from
1950 to the present), EMBASE (via Scopus, from 1980
to the present), and the Cochrane Central Register of
Controlled Trials for eligible studies. Search strategies
are shown in Appendix 1, 2 and 3. No language restric-
tions are set.
Searching for other resources
We will also search three trial registers (www.controlled-
trials.com, www.clinicaltrials.gov, www.who.int/trialsearch/)
to identify additional published or unpublished studies or
data for completed studies as well as ongoing studies. The
reference list of included studies will be screened for fur-
ther eligible studies.
Data collection and analysis
Selection of studies
Firstly, one reviewer will evaluate the titles and abstracts
to determine whether the study meets the eligibility cri-
teria. Secondly, full texts will be evaluated independently
by two reviewers for eligibility. Disagreements will be re-
solved by a discussion with a third reviewer.
Data extraction and management
Two review authors will independently extract data from
the full texts of included studies using a specifically de-
veloped extraction form. The data extraction form will
be piloted previously.
Information will be collected on the following:
1. study characteristics (first author, geographical
origin, year of publication, start and end of study,
study design, number of arms, sample size, duration
of follow-up)
2. participant characteristics (age, sex, numbers
of participants, how diagnosis was performed,
case definitions, disease manifestations, inclusion
and exclusion criteria in the included studies,
baseline imbalances between study arms and
possible confounders (disease manifestation, delay
between onset of symptoms and treatment,
previous treatment, co-medication, co-morbidities
and other confounders as reported by the
authors)
3. intervention and comparator details (sample size for
each treatment arm, blinding, dose and type of
interventions, dosage adjustment based on body
weight, duration of treatment, withdrawals and
drop-outs)4. outcome measures (description of measurement
tools used, data for continuous/dichotomous/
categorical efficacy variables, time point of
measurement, adverse events and serious adverse
events).
When adjusted analyses are available in primary studies,
these adjusted estimates of treatment effects will be
used. Otherwise, we will extract the unadjusted data as
reported in the primary study. This fact will be consid-
ered accordingly in the risk of bias assessment and will
be subject to sensitivity analyses. Data will be entered
into Review Manager (RevMan 5.3) by one of the re-
viewers and checked by a second reviewer. Discrepancies
in data extraction or entry will be resolved by a discus-
sion with a third reviewer. Reviewers will not be blinded
to study author, journal, or institution.
Assessment of risk of bias of included studies
The assessment of risk of bias will be performed by two
reviewers independently considering the following do-
mains according to the Cochrane risk of bias tool: se-
quence generation, allocation concealment, blinding (of
participants, personnel, and outcome assessors), incom-
plete outcome data, selective outcome reporting, and
other sources of bias for the RCTs. According to the
Cochrane Handbook, these items will be described as
having a ‘low’, ‘high’, or ‘unclear’ risk of bias [27]. For
non-randomized studies, bias due to confounding, bias
in selection of participants, bias due to departures from
intended interventions, bias due to missing data, bias in
measurements of outcomes of interventions, bias in se-
lection of the reported results, and overall bias will be
assessed according to the ‘Cochrane risk of bias tool for
non-randomized studies’ [28]. According to the ‘Cochrane
risk of bias tool for non-randomized studies’ these items
will be described as having a ‘low’, ‘moderate’, ‘serious’,
‘critical’, or ‘unclear’ risk of bias. At the time of writ-
ing this protocol, the ‘Cochrane risk of bias tool for
non-randomized studies’ (RoB) is currently being pilo-
ted. Therefore, additionally, the Newcastle-Ottawa Scale
(NOS) will be used to assess risk of bias and methodo-
logical quality [29]. We expect that the major confounders
which could influence effect measures in neuroborreliosis
are ‘time from onset of symptoms until treatment’ and
‘age’. ‘Time from onset of symptoms until treatment’ is in-
cluded in the NOS-rating scale as an assessment factor for
‘comparability’ and is regarded as a major criterion for the
domain ‘bias due to confounding’ in the ‘Cochrane RoB
tool for non-randomized studies’. Non-randomized stud-
ies will be classified as having a ‘high risk’ of bias when
having an assessment as being of ‘serious’ risk in the
Cochrane RoB-tool or when having less than four stars
on the NOS-rating scale. In the event of disagreement,
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review authors. According to the recommendations for
the Cochrane RoB-tool for non-randomized studies, no
studies assessed as having a ‘critical’ risk of bias will be in-
cluded in any data synthesis.
Measures of treatment effect
We will analyze the primary outcome ‘neurological symp-
toms’ as a continuous outcome. If more than one scale is
used to measure outcomes in the same study, only vali-
dated scales will be considered. In the case when more
than one validated or more than one but only unvalidated
scales are reported for one outcome, we will use the re-
sults provided by the scale which is mostly used in the
other included studies. If data does not permit analysis of
‘neurological symptoms’ as a continuous outcome, we will
use the reported data from primary studies and treat this
outcome as a dichotomous outcome ‘presence of neuro-
logical symptoms’. The treatment effect for each continu-
ous outcome (neurological symptoms, disability, patient
reported outcomes, and cerebral fluid pleocytosis) will be
expressed as a mean difference (MD) with 95% confidence
interval (CI). Where continuous outcomes are measured
using different scales, the treatment effect will be ex-
pressed as a standardized mean difference (SMD) with
95% CI. As recommended by Guyatt et al., when possible,
the treatment effects will be additionally expressed by the
ratio of means (RoM) with 95% CI to facilitate interpret-
ation [30,31]. The treatment effect for dichotomous out-
comes (adverse events) will be expressed as a risk ratio
(RR) with 95% confidence intervals.
Unit of analysis
The unit of analysis is each patient recruited in the
studies.
Dealing with missing data
Data will be analyzed on an intention-to-treat basis
whenever possible. If data are only available in graph-
ical format, we will thoroughly estimate the numerical
values.
Assessment of heterogeneity
Heterogeneity among studies will be investigated by
using the chi2 test and I2 test. If significant heterogeneity
is detected (I2 > 50% or p <0.1) for outcome measures,
the calculations with a fixed effect model will be re-
peated using a random effects model as sensitivity ana-
lysis and we will consider results from both.
Assessment of reporting biases
We plan to minimize the impact of reporting bias in our
systematic review by ensuring a comprehensive search for
eligible studies including three trial registries. A funnelplot and appropriate statistical tests for small study effects
will be performed if ≥10 studies are available [32].
Data synthesis
Intervention effects in divergent study designs are in-
fluenced differently by bias. Data from RCTs and non-
randomized studies will not be pooled, but will rather be
analyzed separately. Combined estimates will not be
provided for studies with considerable imbalances or
differences in the included population or differences re-
garding interventions. Estimation of treatment effects will
be based on a fixed effect model; when we are faced with
substantial heterogeneity (i.e., I2 > 50%), a random effects
model will be calculated as well as sensitivity analysis.
Pooling of data and meta-analysis of non-randomized
studies will only be considered among studies with similar
design (e.g., prospective cohort studies will only be com-
bined with other prospective cohort studies) and lim-
ited heterogeneity. We will calculate pooled RRs and
95% CIs across comparable studies using Review Manager
(RevMan 5.3). When considerable heterogeneity (I2 > 80%)
is found between comparable studies, pooled estimates
will not be provided. Instead, a descriptive synthesis of
findings will be performed.
Subgroup analysis and investigation of heterogeneity
We plan subgroup analyses to evaluate effects of differ-
ent lengths of antibiotic treatment regardless of antibiotic
group within prespecified durations (up to 14 days, 14–28
days and longer than 28 days). Due to the clinical im-
portance of antibiotic treatment options, subgroup ana-
lyses focussing on different antibiotics are of considerable
interest. We will evaluate prespecified classes of antibi-
otics (doxycycline, cephalosporins and penicillines, other
antibiotics and combinations of antibiotics) in subgroup
analyses. Cephalosporins and penicillines will be lumped
together as beta-lactam antibiotics to be compared to
other groups of antibiotics. As for the antibiotic agent
doxycycline, the adequate dosage is of particular rele-
vance, a subgroup analysis will be performed comparing
daily doxycycline doses ≤200 mg with doses >200 mg.
Differences in diagnostic likelihood of case definitions
can lead to heterogeneity due to differences in the study
population. The differences between the case definitions
of ‘probable’ and ‘definite’ neuroborreliosis are marginal,
and it is likely that they represent the same population.
In contrast, the case definition of ‘possible’ neuroborre-
liosis has broader inclusion criteria and may contain pa-
tients with other conditions accidentally and therefore
may introduce a different population. A subgroup ana-
lysis will be performed to investigate whether treatment
effects differ in relation to the case definitions used in
the primary studies. As clinical likelihood of diagnosis in
‘probable’ and ‘definite’ neuroborreliosis is very similar,
Dersch et al. Systematic Reviews 2014, 3:117 Page 6 of 8
http://www.systematicreviewsjournal.com/content/3/1/117we will merge these two case definitions to be compared
with ‘possible’ neuroborreliosis cases.
The variety of causative organisms in Europe compared
to the United States could lead to heterogeneity, conse-
quently the effect of geographical origin of the study
population will be evaluated in a subgroup analysis.
Sensitivity analysis
We plan to test the robustness of the results by re-
peating the analysis using a random effects model when
confronted with substantial heterogeneity. Sensitivity
analyses will also be conducted to assess the effect of
risk of bias in the included studies; these sensitivity ana-
lyses will be conducted for both risk of bias assessments
using NOS and the Cochrane NRS tool. If studies with
adjusted and unadjusted data are pooled, the effect of
the studies with unadjusted data will also be subject to
sensitivity analyses. If data permits, we will perform a
sensitivity analysis treating the outcome ‘neurological
symptoms’ as a categorical outcome using a proportional
odds model to assess the robustness of results [33].
Assessing the quality of evidence
We will use the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach
to assess the quality of evidence for each outcome. We
will judge the quality of evidence based on the suggested
five criteria for downrating our confidence in effects es-
timates (risk of bias, inconsistency, imprecision, indirect-
ness, and publication bias) and the three criteria for
uprating our confidence (large effect, dose–response gra-
dient, and opposing confounding). Based on these cri-
teria, the quality of evidence judgment can range from
very low to high.
Discussion
Controversy exists about the choice of drug, route of ad-
ministration, and length of treatment in the therapy of
neuroborreliosis. Evidence from RCTs on this topic are
likely scarce; therefore, we will perform a comprehensive
and systematic overview of the evidence incorporating
RCTs and non-randomized studies examining pharma-
cological treatments for adults with neuroborreliosis.
We will investigate for which intervention efficacy is re-
ported. In this protocol, subgroup analyses and sensitiv-
ity analyses are predefined. Clinical important and much
debated questions regarding differences in effects of var-
ying antibiotic groups and length of antibiotic treatment
will be investigated. Of particular interest is the adequate
dose of doxycycline, which will be investigated separately.
Adverse events of treatments will be evaluated, for which
non-randomized studies are particularly valuable. Differ-
ent to previous conducted reviews, another advantage will
be the systematic assessment of risk of bias [16]. Ourresults will be important to clarify controversies and re-
duce uncertainty both for patients and healthcare pro-
viders. The summary and evaluation of the available body
of evidence may lead to evidence based treatment recom-
mendations for neuroborreliosis. Implications for future
research can be drawn from the results.
Appendix 1 Ovid MEDLINE search strategy

























26. (nerve adj5 damage*).mp.
27. (nerve adj5 involvement).mp.
28. bannwarth*.mp.
29. vasculitis/




34. 7 and 33
Appendix 2 SCOPUS search strategy
1. TITLE-ABS-KEY(lyme*) OR TITLE-ABS-KEY
(neuroborreliosis) OR TITLE-ABS-KEY(borreli*) OR
TITLE-ABS-KEY(erythema migrans)
2. TITLE-ABS-KEY(brain*) OR TITLE-ABS-KEY
(mening*) OR TITLE-ABS-KEY(spinal*) OR TITLE-
ABS-KEY(encephal*) OR TITLE-ABS-KEY(radiculi*)
OR TITLE-ABS-KEY(radiculo*) OR TITLE-ABS-KEY
(facial pal*) OR TITLE-ABS-KEY(facial par*) OR
TITLE-ABS-KEY(myel*) OR TITLE-ABS-KEY
(nervous system dis*) OR TITLE-ABS-KEY(neur*) OR
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(polyradicul*) OR TITLE-ABS-KEY(mononeur*) OR
TITLE-ABS-KEY(nerve AND damage*) OR TITLE-
ABS-KEY(nerve AND involve*) OR TITLE-ABS-KEY
(bannwarth*) OR TITLE-ABS-KEY(vasculiti*) OR
TITLE-ABS-KEY(cranial nerve*)
3. 1 AND 2
Appendix 3 CENTRAL search strategy
1. MeSH descriptor: [Borrelia] explode all trees
2. MeSH descriptor: [Lyme Disease] explode all trees
3. *borreli*
4. erythem* near/2 migran*
5. lyme*
6. 1 OR 2 OR 3 OR 4 OR 5
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